Lepu Medical(SZ:300003) news flash·2025-08-01 11:53Core Viewpoint - Lepu Medical's subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for its self-developed injectable recombinant type A botulinum toxin, indicating a significant advancement in the company's dermatology product portfolio [1] Group 1 - The approved product is intended for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1] - The successful progress of this research project highlights the company's strong and efficient R&D capabilities in the dermatology field [1] - This development enriches the company's product layout in dermatology, enhancing its core competitiveness in this niche market [1] Group 2 - The new product is expected to support the company's long-term development in the consumer healthcare market [1]